Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Can aging be treated? Evidence, hype and the regulatory gap

    Aging interventions extend lifespan in mice and the first partial reprogramming therapy is in a human trial, but human randomized evidence is thin, aging biomarkers are not validated, and peer-reviewed reviews note that the FDA does not recognize aging as a disease.[1][2][3][4] This page separates what is established from what is claimed, and sets out the competing views.

    Editor reviewedStrict sourcingUpdated Aging and longevity biologyHealth and medicineLife sciences
    Show:

    The question

    Age-related decline is the main risk factor for cancer, diabetes, cardiovascular disease and neurodegeneration.[5] The geroscience hypothesis says that slowing aging could delay many of these at once.[6] Two linked debates follow. Is the evidence strong enough to say aging can be treated in people? And should regulators treat aging as a condition that drugs can target?

    What is established

    In laboratory mammals, aging can be delayed with genetic, dietary and drug-based approaches.[7] Rapamycin extended lifespan in both sexes of mice in 2009, even when started late in life.[1] An anti-IL-11 antibody extended median mouse lifespan by 22.5% in males and 25% in females in 2024.[8] Partial reprogramming reversed vision loss in aged mice.[9]

    Mouse results come with caveats. Most compounds that extended lifespan in the NIA’s testing program worked mainly or only in males.[10] Whether metformin “worked” in mice depended on the statistical test used.[11]

    What human trials show

    Randomized human evidence is limited and mixed. A senolytic trial in 60 postmenopausal women missed its primary bone endpoint.[12] A senolytic eye injection showed a non-significant trend in 65 patients.[13] The mTOR inhibitor RTB101 did not reduce respiratory illness in a 1,024-person phase 3 trial.[14] In PEARL, low-dose rapamycin did not change its primary outcome. Several authors were employees and shareholders of AgelessRx.[15][16] Caloric restriction slowed one epigenetic pace-of-aging measure in CALERIE, with small effects and no significant change on other clocks.[17]

    The newest human milestone is the first partial reprogramming trial. Early company-reported data from three patients showed no serious adverse events in a study designed to test safety.[18][19]

    The measurement problem

    Aging biomarkers could serve as surrogate endpoints, but as of 2024 there was no consensus on how to validate them.[3] Technical noise can shift some epigenetic clocks by up to 9 years between replicate measurements.[20] Some clock developers have commercial ties; DunedinPACE, for example, is licensed to a testing company.[21] Even the field’s foundations are contested: a 2024 survey of researchers found no majority view on what aging or rejuvenation is.[22]

    Taken together, the evidence supports a narrow conclusion: several mechanisms of aging can be manipulated in animals, and some interventions appear safe enough to test in people. It does not yet support claims that any product slows or reverses human aging. The gap between those two statements is where most hype in the field sits. The commercial ties seen in clock licensing and in some trial authorship are a reason to look for independent replication.

    The regulatory gap

    Peer-reviewed papers from 2025 state that the FDA does not recognize aging as a disease and that no regulatory framework exists for approving aging-targeted therapies, which are therefore developed through disease-specific pipelines; ER-100, for example, is being tested in glaucoma and NAION.[4][2] TAME was designed to measure a composite of cardiovascular events, cancer, dementia and death, and its designers present it as a shift toward targeting aging itself.[23][24] In veterinary medicine, the FDA has accepted the effectiveness section of Loyal’s application for LOY-002, a drug intended to extend dogs’ lifespan. Manufacturing review remains.[25][26]

    The disease-by-disease route has a practical logic: it lets companies test aging mechanisms under existing rules. Its cost is that a drug’s broader effect on aging may never be formally evaluated. A veterinary decision on LOY-002 would not change human rules, but it would give the field its first regulator-reviewed lifespan claim in any species, if the drug is approved.

    What to watch

    Over the next year, the most informative signals are likely to be higher-dose safety data and any longer-term follow-up from the ER-100 trial; the FDA’s manufacturing review of LOY-002; outcome data from TRIAD and the XPRIZE Healthspan finalists’ trials; and progress on biomarker validation standards. A large human trial with hard endpoints, which researchers say is needed for a conclusive test, is unlikely to report within that window.[27][26][28][29][30]

    Competing views

    Aging should be a treatable indication

    Because aging is the main shared risk factor for chronic disease, targeting it could delay many diseases at once, and composite-endpoint trials such as TAME were designed to give regulators a path.[5][6][24][23]

    The human evidence is not there yet

    Randomized human trials of senolytics and mTOR inhibitors have mostly missed primary endpoints, and mouse results often depend on sex and statistical method, so claims of human age reversal run ahead of the data.[12][15][14][10][11]

    Measure first, then treat

    Progress depends on validated biomarkers that could serve as surrogate endpoints, but clocks are noisy, disagree with one another and lack agreed validation standards.[3][20][17][31]

    Questions readers ask

    Does the FDA consider aging a disease?

    No. Peer-reviewed papers from 2025 state that the FDA does not recognize aging as a disease and that no regulatory framework exists for approving therapies that target aging, so such therapies are developed for specific diseases.[4]

    Is there good human evidence that any drug slows aging?

    Not from large randomized trials with hard outcomes. Researchers say a conclusive test would need long follow-up measuring chronic disease and death.[30]

    Can an epigenetic age test show that a treatment worked?

    Not reliably yet. Some clocks vary by up to 9 years between repeat measurements, and there is no consensus on how to validate aging biomarkers as trial endpoints.[20][3]

    Do aging researchers agree on what aging is?

    No. A 2024 survey found no majority view on what aging is, what causes it, or what counts as rejuvenation.[22]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      In 2009 rapamycin, an inhibitor of the mTOR pathway, extended median and maximal lifespan in both male and female mice when feeding began at 600 days of age, the first drug shown to extend lifespan in both sexes of a mammal. confirmedas of 2009-07-08

    2. [2]

      On 9 June 2026 Life Biosciences announced the first patient dosed in its Phase 1 trial of ER-100 (NCT07290244) in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), which evaluates safety and tolerability with additional visual-function endpoints. confirmedas of 2026-06-09

    3. [3]

      Aging biomarkers could serve as surrogate endpoints for trials of longevity interventions, but as of 2024 there was no consensus on how they should be validated before clinical use. confirmedas of 2024-02-14

    4. [4]

      Papers published in 2025 in peer-reviewed journals state that the FDA does not recognize aging as a disease and that no regulatory framework exists for developing or approving therapies that target aging, so such therapies are developed through disease-specific pipelines. confirmedas of 2025-08-04

    5. [5]

      Age-related loss of physiological integrity is the primary risk factor for major human diseases including cancer, diabetes, cardiovascular disorders and neurodegenerative diseases. confirmedas of 2013-06-06

    6. [6]

      The geroscience hypothesis proposes that therapies slowing or reversing molecular changes of aging could delay or prevent multiple chronic diseases at once and extend healthy lifespan. confirmedas of 2023-02-09

    7. [7]

      Aging in mammals can be delayed in the laboratory with genetic, dietary and drug-based approaches. confirmedas of 2014-11-06

    8. [8]

      In a 2024 Nature study, an anti-IL-11 antibody given to mice from 75 weeks of age until death extended median lifespan by 22.5% in males and 25% in females. confirmedas of 2024-07-17

    9. [9]

      In 2020, expressing three factors (Oct4, Sox2 and Klf4, or OSK) in mouse retinal ganglion cells restored youthful DNA methylation patterns, promoted nerve regeneration and reversed vision loss in a glaucoma model and in aged mice. confirmedas of 2020-12-02

    10. [10]

      Most compounds that extended lifespan in the ITP worked primarily or only in male mice. confirmedas of 2025-07-24

    11. [11]

      A 2024 reanalysis of ITP data from 2004 to 2022 with the Gehan test, which is more sensitive to mortality differences earlier in life, found that metformin, previously missed by the log-rank test, increased survival in male mice only. confirmedas of 2024-04-17

    12. [12]

      In a 2024 phase 2 randomized trial in 60 postmenopausal women, intermittent dasatinib plus quercetin did not change the primary bone-resorption marker at 20 weeks compared with control. confirmedas of 2024-07-02

    13. [13]

      In a 65-person sham-controlled trial in diabetic macular edema, UBX1325 showed a non-significant 5.6-letter visual acuity advantage at 48 weeks, and the authors called for larger trials. confirmedas of 2025-04-22

    14. [14]

      In a phase 3 trial of 1,024 adults aged 65 or older, the mTOR inhibitor RTB101 did not reduce clinically symptomatic respiratory illness compared with placebo. confirmedas of 2021-05-06

    15. [15]

      In PEARL, adverse events were similar across groups and the primary outcome, visceral fat, did not change significantly; some secondary measures improved, such as lean tissue mass and pain in women on 10 mg. confirmedas of 2025-04-04

    16. [16]

      Several PEARL authors disclosed that they are employees and shareholders of AgelessRx, a company that provides longevity-focused prescriptions. confirmedas of 2025-04-04

    17. [17]

      In a post hoc analysis of CALERIE, caloric restriction slowed DunedinPACE but did not significantly change biological age estimates from other clocks including PhenoAge and GrimAge, and effect sizes were small. confirmedas of 2023-02-09

    18. [18]

      In first-in-human data released on 8 October 2026, three open-angle glaucoma participants given the lowest ER-100 dose had no dose-limiting toxicities or serious adverse events. confirmedas of 2026-10-08

    19. [19]

      The company reported visual-field improvements in two of the three participants at day 56, in a Phase 1 study designed to assess safety rather than efficacy. reportedas of 2026-10-08

    20. [20]

      Technical noise in DNA methylation data can make six prominent epigenetic clocks disagree by up to 9 years between replicate measurements of the same sample. confirmedas of 2022-07-15

    21. [21]

      DunedinPACE is a Duke University and University of Otago invention licensed to the testing company TruDiagnostic, according to conflict-of-interest disclosures in a 2023 consensus paper. confirmedas of 2023-08-31

    22. [22]

      A 2024 survey of aging researchers found no consensus, and not even a majority view, on core questions such as what aging is, what causes it, when it begins and what counts as rejuvenation. confirmedas of 2024-12-03

    23. [23]

      TAME's primary measure is time to a new occurrence of a composite of cardiovascular events, cancer, dementia and death, rather than any single disease. confirmedas of 2016-06-14

    24. [24]

      TAME's designers present it as an initial step toward more effective next-generation drugs, and say a positive result would mark a shift from treating each medical condition separately to targeting aging itself. confirmedas of 2016-06-14

    25. [25]

      In February 2025 the FDA's Center for Veterinary Medicine accepted the reasonable expectation of effectiveness (RXE) section for Loyal's LOY-002, a daily pill intended to extend lifespan in senior dogs. confirmedas of 2025-02-26

    26. [26]

      The manufacturing section must still be accepted before LOY-002 can be considered for conditional approval; as of October 2026 Loyal says two of three major requirements are complete and approval is not guaranteed. confirmedas of 2026-10-10

    27. [27]

      The trial's data safety monitoring board recommended escalating to the second dose level in glaucoma participants, and the trial is ongoing. confirmedas of 2026-10-08

    28. [28]

      TRIAD is a double-masked, randomized, placebo-controlled multicenter trial testing whether rapamycin extends lifespan and improves healthspan in healthy middle-aged companion dogs from the Dog Aging Project. confirmedas of 2025-02-14

    29. [29]

      Teams in the XPRIZE Healthspan finals must be prepared to run randomized controlled clinical trials in 100 to 200 participants. confirmedas of 2026-10-10

    30. [30]

      Researchers note that a conclusive test of the geroscience hypothesis requires long trials measuring hard endpoints such as chronic disease incidence and mortality. confirmedas of 2023-02-09

    31. [31]

      A 2023 consensus paper by the Biomarkers of Aging Consortium said the lack of standards and consensus on what makes a reliable aging biomarker hinders their development and clinical validation. confirmedas of 2023-08-31

    Revision history (1)
    1. Page created.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Can aging be treated? Evidence, hype and the regulatory gap." ContentLora, updated Oct 10, 2026. https://contentlora.com/analysis/aging-as-a-disease-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents